Bibliography
- Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60(8):1119-22
- Thal LJ, Carta A, Doody R, et al. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(Suppl 3):46-9
- Perl DP. Neuropathology of Alzheimer's disease and related disorders. Neurol Clin 2000;18(4):847-64
- Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976;99(3):459-96
- Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215(4537):1237-9
- Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol 1983;61(2):101-8
- Bartus RT, Flicker C, Dean RL, et al. Behavioral and biochemical effects of nucleus basalis magnocellularis lesions: implications and possible relevance to understanding or treating Alzheimer's disease. Prog Brain Res 1986;70:345-61
- Pogacic V, Herrling P. List of drugs in development for neurodegenerative diseases. Update June 2007. Neurodegener Dis 2007;4(6):443-86
- Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 2001;49(3):200-10
- Newhouse PA, Potter A, Kelton M, Corwin J. Nicotinic treatment of Alzheimer's disease. Biol Psychiatry 2001;49(3):268-78
- Dunbar GC, Inglis F, Kuchibhatla R, et al. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 2007;21(2):171-8
- Mazurov A, Hauser T, Miller CH. Selective alpha7 nicotinic acetylcholine receptor ligands. Curr Med Chem 2006;13(13):1567-84
- Mattson MP, Pedersen WA, Duan W, et al. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann NY Acad Sci 1999;893:154-75
- Rothman SM, Thurston JH, Hauhart RE. Delayed neurotoxicity of excitatory amino acids in vitro. Neuroscience 1987;22(2):471-80
- Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348(14):1333-41
- Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291(3):317-24
- Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14(2):135-46
- van Dyck CH, Tariot PN, Meyers B, Malca RE. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21(2):136-43
- Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006
- Lundbeck H. Available from: www.forestclinicaltrials.com.2004
- McShane R, Areosa SA, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;(2):CD003154
- Staubli U, Perez Y, Xu FB, et al. Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc Natl Acad Sci USA 1994;91(23):11158-62
- Ingvar M, Ambros-Ingerson J, Davis M, et al. Enhancement by an ampakine of memory encoding in humans. Exp Neurol 1997;146(2):553-9
- Lynch G, Kessler M, Rogers G, et al. Psychological effects of a drug that facilitates brain AMPA receptors. Int Clin Psychopharmacol 1996;11(1):13-9
- Lynch G, Granger R, Ambros-Ingerson J, et al. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol 1997;145(1):89-92
- Wezenberg E, Verkes RJ, Ruigt GS, et al. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 2007;32(6):1272-83
- Jhee SS, Chappell AS, Zarotsky V, et al. Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects. J Clin Pharmacol 2006;46(4):424-32
- Panula P, Rinne J, Kuokkanen K, et al. Neuronal histamine deficit in Alzheimer's disease. Neuroscience 1998;82(4):993-7
- Witkin JM, Nelson DL. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004;103(1):1-20
- Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 2003;136(5):474-7
- Available from: www.medivation.com/pipeline_dimebon.html
- Available from: www.alzforum.org/new/detail.asp?id=1590
- Available from: www.medivation.com/pipeline_alzheimer.html
- Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006;60(1):145-7
- Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283(12):1571-7
- Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003;100(18):10417-22
- Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 2001;24(4):219-24
- Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 2005;115(5):1121-9
- Gelinas DS, DaSilva K, Fenili D, et al. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 2004;101(Suppl 2):14657-62
- Tariot PN. Clinical trials of amyloid-based therapies for Alzheimer's disease. CNS Spectr 2007;12(1 Suppl 1):7-10
- Walker LC, Ibegbu CC, Todd CW, et al. Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Biochem Pharmacol 2005;69(7):1001-8
- Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400(6740):173-7
- Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408(6815):979-82
- Sigurdsson EM, Scholtzova H, Mehta PD, et al. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001;159(2):439-47
- Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6(8):916-9
- Lombardo JA, Stern EA, McLellan ME, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003;23(34):10879-83
- Wilcock DM, DiCarlo G, Henderson D, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 2003;23(9):3745-51
- Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408(6815):982-5
- Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002;22(15):6331-5
- Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006;281(7):4292-9
- Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64(9):1553-62
- Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61(1):46-54
- Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9(4):448-52
- Orgogozo JM. Vaccination treatment of AD (abstract S5-04-04). 2006. p. S94
- Available from: www.clinicaltrials.gov/ct2/show/NCT00479557?term=acc-001&rank=1
- Woodhouse A, Dickson TC, Vickers JC. Vaccination strategies for Alzheimer's disease: a new hope? Drugs Aging 2007;24(2):107-19
- DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98(15):8850-5
- Matsuoka Y, Saito M, LaFrancois J, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003;23(1):29-33
- Bales KR, Tzavara ET, Wu S, et al. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J Clin Invest 2006;116(3):825-32
- Available from: www.elan.com/news/2007/20070521.asp
- Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol 2003;2(4):215-20
- Du Y, Wei X, Dodel R, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003;126(Pt 9):1935-9
- Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75(10):1472-4
- Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2008
- Available from: www.baxter.com/about_baxter/news_room/news_releases/2007/08-28-07-ivig.html
- Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004;5(9):677-85
- Hills ID, Vacca JP. Progress toward a practical BACE-1 inhibitor. Curr Opin Drug Discov Devel 2007;10(4):383-91
- Evin G, Sernee MF, Masters CL. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 2006;20(5):351-72
- Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann Rev Pharmacol Toxicol 2003;43:545-84
- Pollack SJ, Lewis H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 2005;6(1):35-47
- Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279(13):12876-82
- Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005;28(3):126-32
- Available from: www.newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=302104
- Rosen LB, Stone J, Plump A, et al. The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. 2nd edition. 2006. p. S79
- Beher D, Clarke EE, Wrigley JD, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 2004;279(42):43419-26
- Weggen S, Eriksen JL, Sagi SA, et al. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003;278(33):30748-54
- Townsend KP, Pratico D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005;19(12):1592-601
- Wilcock G, Black S, Haworth J, et al. A Placebo- controlled, Double-blind Trial of the Selective Aâ-42 Lowering Agent, Flurizan (MPC-7869, (R)-flurbiprofen) in Patients with Mild to Moderate Alzheimer's Disease. 2005 B.C
- Available from: www.myriad.com/alzheimers/flurizan.php
- Gasparini L, Ongini E, Wilcock D, Morgan D. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev 2005;48(2):400-8
- Wallace JL, Muscara MN, de NG, et al. Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1′-biphenyl]-4-acetyloxy)-3-methoxyphenyl] -2-propenoic acid 4-nitrooxy butyl ester]. J Pharmacol Exp Ther 2004;309(2):626-33
- Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992;359(6393):325-7
- Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992;258(5079):126-9
- Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Ann Rev Neurosci 2003;26:267-98
- Hull M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs 2006;66(16):2075-93
- Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006;67(10):1757-63
- Available from: www.alzforum.org/drg/drc/detail.asp?id=84
- Available from: www.transitiontherapeutics.com/technology/alzheimers.php
- Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000;356(9242):1627-31
- Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57(10):1439-43
- Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52(3):346-50
- Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62(5):753-7
- Kivipelto M, Solomon A, Winblad B. Statin therapy in Alzheimer's disease. Lancet Neurol 2005;4(9):521-2
- Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30(3):665-76
- Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60(12):1685-91
- Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 2000;20(Suppl):S20-4
- Available from: www.pranabio.com
- Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21(21):8370-7
- Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004;75(6):742-50
- Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280(7):5892-901
- Available from: www.clinicaltrials.gov/ct2/show/NCT00099710?term=curcumin&rank=8
- Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006;20(4):298-301
- Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001;86(9):4398-405
- Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13(11):950-8
- Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6(4):246-54
- Available from: www.alzforum.org/drg/drc/detail.asp?id=116
- Kalmijn S, Launer LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997;42(5):776-82
- Barberger-Gateau P, Letenneur L, Deschamps V, et al. Fish, meat, and risk of dementia: cohort study. BMJ 2002;325(7370):932-3
- Lauritzen L, Hansen HS, Jorgensen MH, Michaelsen KF. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res 2001;40(1-2):1-94
- Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006;83(6 Suppl):S1467-76
- Available from: www.clinicaltrials.gov/ct/show/NCT00440050
- Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293(5534):1487-91
- Gotz J, Chen F, van DJ, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293(5534):1491-5
- Bennett DA, Schneider JA, Wilson RS, et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004;61(3):378-84
- Grober E, Dickson D, Sliwinski MJ, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging 1999;20(6):573-9
- Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol 1985;101(4):1371-8
- Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005;1739(2-3):280-97
- Churcher I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr Top Med Chem 2006;6(6):579-95
- Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007;6(6):464-79
- Tanzi RE. Tangles and neurodegenerative disease - a surprising twist. N Engl J Med 2005;353(17):1853-5
- SantaCruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005;309(5733):476-81
- Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 2007;4(5):507-9
- Available from: www.allontherapeutics.com/pd_AL-108.htm
- Available from: www.neuropharma.es
- Available from: www.clinicaltrials.gov/ct2/show/NCT00515333?spons=%22TauRx+Therapeutics+Ltd%22&spons_ex=Y&rank=1
- Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002;54(12):1567-77
- Mark RJ, Ashford JW, Goodman Y, Mattson MP. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 1995;16(2):187-98
- Kim AJ, Shi Y, Austin RC, Werstuck GH. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J Cell Sci 2005;118(Pt 1):89-99
- Available from: www.nia.nih.gov/Alzheimers/ResearchInformation/NewsReleases/Archives/PR2006/PR20061017ADCS.htm
- Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71(2):S621-9
- Rutten BP, Steinbusch HW, Korr H, Schmitz C. Antioxidants and Alzheimer's disease: from bench to bedside (and back again). Curr Opin Clin Nutr Metab Care 2002;5(6):645-51
- Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med 2000;109(7):577-85
- Ramassamy C, Averill D, Beffert U, et al. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis 2000;7(1):23-37
- Tatton WG. Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 1993;8(Suppl 1):S20-30
- Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003;(1):CD000442
- Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336(17):1216-22
- Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352(23):2379-88
- Bastianetto S, Ramassamy C, Dore S, et al. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 2000;12(6):1882-90
- Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2005;2(5):541-51
- DeKosky ST, Fitzpatrick A, Ives DG, et al. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 2006;27(3):238-53
- Fritze J, Walden J. Clinical findings with nimodipine in dementia: test of the calcium hypothesis. J Neural Transm Suppl 1995;46:439-53
- Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002;(3):CD000147
- Available from: www.memorypharma.com
- Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11(5):551-5
- Available from: www.ceregene.com/press_050207.asp
- Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset alzheimer's dementia. Proc Natl Acad Sci USA 2004;101(1):284-9
- Available from: www.adni-info.org/
- Available from: http://www.alzstudygroup.org
- Tariot PN, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord 2003;17(Suppl 4):S105-13